Cargando…

Serum metabolites as biomarkers in systemic sclerosis-associated interstitial lung disease

Systemic sclerosis (SSc) is a severe multi-organ disease with interstitial lung disease (ILD) being the major cause of death. While targeted therapies are emerging, biomarkers for sub-stratifying patients based on individual profiles are lacking. Herein, we investigated how levels of serum metabolit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Meier, C., Freiburghaus, K., Bovet, C., Schniering, J., Allanore, Y., Distler, O., Nakas, C., Maurer, B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7736572/ https://www.ncbi.nlm.nih.gov/pubmed/33318574 http://dx.doi.org/10.1038/s41598-020-78951-6

Ejemplares similares

Computed tomography-based radiomics decodes prognostic and molecular differences in interstitial lung disease related to systemic sclerosis
por: Schniering, Janine, et al.
Publicado: (2022)

Applicability of radiomics in interstitial lung disease associated with systemic sclerosis: proof of concept
por: Martini, K., et al.
Publicado: (2020)

Evaluation of (99m)Tc-rhAnnexin V-128 SPECT/CT as a diagnostic tool for early stages of interstitial lung disease associated with systemic sclerosis
por: Schniering, Janine, et al.
Publicado: (2018)

Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database
por: Hoffmann-Vold, Anna-Maria, et al.
Publicado: (2021)

Tie2 as a novel key factor of microangiopathy in systemic sclerosis
por: Moritz, Falk, et al.
Publicado: (2017)

Continued treatment with nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from SENSCIS-ON
por: Allanore, Yannick, et al.
Publicado: (2022)

The role of antifibrotic therapies in the treatment of systemic sclerosis–associated interstitial lung disease
por: Boleto, Gonçalo, et al.
Publicado: (2022)

Patient preferences for the treatment of systemic sclerosis-associated interstitial lung disease: a discrete choice experiment
por: Bruni, Cosimo, et al.
Publicado: (2022)

Predictors of progression in systemic sclerosis patients with interstitial lung disease
por: Distler, Oliver, et al.
Publicado: (2020)

Treatment of systemic sclerosis: is there any hope for the future?
por: Allanore, Yannick, et al.
Publicado: (2016)

Nintedanib in Patients With Systemic Sclerosis–Associated Interstitial Lung Disease: Subgroup Analyses by Autoantibody Status and Modified Rodnan Skin Thickness Score
por: Kuwana, Masataka, et al.
Publicado: (2022)

Circulating Biomarkers of Interstitial Lung Disease in Systemic Sclerosis
por: Lota, Harpreet K., et al.
Publicado: (2012)

Effect of Nintedanib on Progression of Systemic Sclerosis‐Associated Interstitial Lung Disease Over 100 Weeks: Data From a Randomized Controlled Trial
por: Assassi, Shervin, et al.
Publicado: (2022)

Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group
por: Adler, Sabine, et al.
Publicado: (2018)

Increased frequency of circulating Th22 in addition to Th17 and Th2 lymphocytes in systemic sclerosis: association with interstitial lung disease
por: Truchetet, Marie-Elise, et al.
Publicado: (2011)

Improving risk-stratification of rheumatoid arthritis patients for interstitial lung disease
por: Avouac, Jérôme, et al.
Publicado: (2020)

(18)F-AzaFol for Detection of Folate Receptor-β Positive Macrophages in Experimental Interstitial Lung Disease—A Proof-of-Concept Study
por: Schniering, Janine, et al.
Publicado: (2019)

Serum biomarkers in interstitial lung diseases
por: Tzouvelekis, Argyris, et al.
Publicado: (2005)

Prediction of improvement in skin fibrosis in diffuse cutaneous systemic sclerosis: a EUSTAR analysis
por: Dobrota, Rucsandra, et al.
Publicado: (2016)

Transferability of radiomic signatures from experimental to human interstitial lung disease
por: Gabryś, Hubert S., et al.
Publicado: (2022)

Biomarkers in systemic sclerosis-associated interstitial lung disease: review of the literature
por: Bonhomme, Olivier, et al.
Publicado: (2019)

Etiology, Risk Factors, and Biomarkers in Systemic Sclerosis with Interstitial Lung Disease
por: Khanna, Dinesh, et al.
Publicado: (2020)

Dyspnoea and cough in patients with systemic sclerosis–associated interstitial lung disease in the SENSCIS trial
por: Volkmann, Elizabeth R, et al.
Publicado: (2022)

Serum TARC Levels in Patients with Systemic Sclerosis: Clinical Association with Interstitial Lung Disease
por: Kuzumi, Ai, et al.
Publicado: (2021)

Epidemiology of systemic sclerosis and systemic sclerosis-associated interstitial lung disease
por: Bergamasco, Aurore, et al.
Publicado: (2019)

Decline in forced vital capacity in subjects with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial compared with healthy reference subjects
por: Maher, Toby M., et al.
Publicado: (2022)

Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression
por: Khanna, Dinesh, et al.
Publicado: (2023)

Serum cold-inducible RNA-binding protein levels as a potential biomarker for systemic sclerosis-associated interstitial lung disease
por: Omori, Issei, et al.
Publicado: (2023)

Interstitial lung disease pathology in systemic sclerosis
por: Konopka, Kristine E., et al.
Publicado: (2021)

Protein biomarkers of disease progression in patients with systemic sclerosis associated interstitial lung disease
por: Cerro-Chiang, Giuliana, et al.
Publicado: (2023)

Soluble CD163 as a Potential Biomarker in Systemic Sclerosis
por: Frantz, Camelia, et al.
Publicado: (2018)

Impact of lung function decline on time to hospitalisation events in systemic sclerosis-associated interstitial lung disease (SSc-ILD): a joint model analysis
por: Kreuter, Michael, et al.
Publicado: (2022)

Screening and identification of potential biomarkers and therapeutic targets for systemic sclerosis-associated interstitial lung disease
por: Huang, Biqing, et al.
Publicado: (2021)

Recent Treatments of Interstitial Lung Disease with Systemic Sclerosis
por: Yasuoka, Hidekata
Publicado: (2016)

Pathogenesis of systemic sclerosis associated interstitial lung disease
por: Nihtyanova, Svetlana I, et al.
Publicado: (2020)

Diagnosis and monitoring of systemic sclerosis-associated interstitial lung disease using high-resolution computed tomography
por: Khanna, Dinesh, et al.
Publicado: (2022)

B Cell Depletion Treatment in Resistant Systemic Sclerosis Interstitial Lung Disease
por: Bounia, Constantina A., et al.
Publicado: (2022)

Incidence and prevalence of systemic sclerosis and systemic sclerosis with interstitial lung disease in the United States
por: Fan, Yanni, et al.
Publicado: (2020)

Small airways dysfunction in patients with systemic sclerosis and interstitial lung disease
por: Panagopoulos, Panagiotis K., et al.
Publicado: (2022)

IL-13 and IL-33 Serum Levels Are Increased in Systemic Sclerosis Patients With Interstitial Lung Disease
por: Versace, Antonio Giovanni, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_olgv8o8vuqtoq3kahso77i0psb